Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cancer chemotherapy [[electronic resource] /] / Rachel Airley
| Cancer chemotherapy [[electronic resource] /] / Rachel Airley |
| Autore | Airley Rachel |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina |
616.99/4061
616.994061 |
| Soggetto topico |
Cancer - Chemotherapy
Chemotherapy |
| ISBN |
1-282-11217-1
9786612112171 0-470-09254-8 0-470-09256-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction
5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction 11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors 14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase 21 Histone deacetylase: an epigenetic drug target |
| Record Nr. | UNINA-9910782612503321 |
Airley Rachel
|
||
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer chemotherapy [[electronic resource] /] / Rachel Airley
| Cancer chemotherapy [[electronic resource] /] / Rachel Airley |
| Autore | Airley Rachel |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
| Descrizione fisica | 1 online resource (362 p.) |
| Disciplina |
616.99/4061
616.994061 |
| Soggetto topico |
Cancer - Chemotherapy
Chemotherapy |
| ISBN |
1-282-11217-1
9786612112171 0-470-09254-8 0-470-09256-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction
5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction 11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors 14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase 21 Histone deacetylase: an epigenetic drug target |
| Record Nr. | UNINA-9910825509203321 |
|
Airley Rachel
|
||
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||